Catherine Vilchèze

发表

Addressing the Metabolic Stability of Antituberculars through Machine Learning.

William R. Jacobs, Sean Ekins, Riccardo Russo, 2017, ACS medicinal chemistry letters.

Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosis

Joel S. Freundlich, James C Sacchettini, Joel S Freundlich, 2009, ChemMedChem.

The mechanism of isoniazid killing: clarity through the scope of genetics.

Catherine Vilchèze, C. Vilchèze, W. Jacobs, 2007, Annual review of microbiology.

Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis

David Alland, James C Sacchettini, Catherine Vilchèze, 2008, Molecular microbiology.

Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis

Gulcin Gulten, Catherine Vilchèze, C. Vilchèze, 2010, Molecular microbiology.

Novel Inhibitors of InhA Efficiently Kill Mycobacterium tuberculosis under Aerobic and Anaerobic Conditions

James C. Sacchettini, William R. Jacobs, David Alland, 2011, Antimicrobial Agents and Chemotherapy.

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

Peter G. Schultz, Feng Wang, William R. Jacobs, 2015, Proceedings of the National Academy of Sciences.

Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids.

James C Sacchettini, Catherine Vilchèze, Robert Bittman, 2006, Chemistry & biology.

Biological Evaluation of Potent Triclosan‐Derived Inhibitors of the Enoyl–Acyl Carrier Protein Reductase InhA in Drug‐Sensitive and Drug‐Resistant Strains of Mycobacterium tuberculosis

Shichun Lun, Joel S. Freundlich, Xin Wang, 2014, ChemMedChem.

Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

William R. Jacobs, John T. Welch, Catherine Vilchèze, 2000, Nature Medicine.